Capricor Therapeutics, Inc.
CAPR
$6.97
$0.081.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -7.92% | -63.44% | 1.38% | 64.29% | 1,159.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.92% | -63.44% | 1.38% | 64.29% | 1,159.31% |
| Cost of Revenue | 46.42% | 17.74% | 41.82% | 44.89% | 59.51% |
| Gross Profit | -259.43% | -148.39% | -74.15% | -32.50% | 140.74% |
| SG&A Expenses | 24.62% | 14.64% | 7.40% | 16.01% | 22.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.83% | 17.02% | 33.42% | 35.82% | 48.12% |
| Operating Income | -500.78% | -89.52% | -49.62% | -25.43% | 84.12% |
| Income Before Tax | -833.81% | -96.49% | -49.32% | -26.08% | 90.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -833.81% | -96.49% | -49.32% | -26.08% | 90.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -833.81% | -96.49% | -49.32% | -26.08% | 90.13% |
| EBIT | -500.78% | -89.52% | -49.62% | -25.43% | 84.12% |
| EBITDA | -651.99% | -91.99% | -49.94% | -24.89% | 87.64% |
| EPS Basic | -542.17% | -53.33% | -18.78% | -1.53% | 91.88% |
| Normalized Basic EPS | -534.19% | -53.43% | -18.82% | -1.51% | 91.88% |
| EPS Diluted | -542.17% | -53.33% | -18.78% | -0.77% | 91.88% |
| Normalized Diluted EPS | -534.19% | -53.43% | -18.82% | -1.51% | 91.88% |
| Average Basic Shares Outstanding | 45.15% | 28.17% | 25.68% | 24.19% | 21.86% |
| Average Diluted Shares Outstanding | 45.15% | 28.17% | 25.68% | 24.19% | 21.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |